Tag "3"

GlobeImmune Hep B drug fails mid-stage study, shares plunge

Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company’s shares down as much as 60 percent to a record low. GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for hepatitis B treatments as hepatitis C drugs flood the market. Hepatitis